Clear Street’s LakeShore Biopharma LSB Stock Holding History

Clear Street’s Portfolio LSB Stock Details LSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10	Closed	-$160	–	1375
2023 Q1	$160	Buy	+10	New	+$507	﹤0.01%	1089

Other funds holding LSB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

VAM

Valliance Asset Management Central, Hong Kong $864M AUM 906.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

SLM

Snow Lake Management Menlo Park, California $90.7M AUM 72.65% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

FSI

Flow State Investments Chicago, Illinois $245M AUM 5.06% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Clear Street's LSB Position: Q2 2023 in Review

Clear Street sold out of LakeShore Biopharma (LSB) in Q2 2023, closing a stake of 10 shares — an estimated $160 sold.

Clear Street first reported a position in LSB in Q1 2023 and held it in 1 quarter. The position peaked at $160 in Q1 2023. 16 funds tracked by Wall St. Rank hold LSB as of Q2 2023.

Clear Street reported no remaining LakeShore Biopharma position as of Q2 2023 after selling out during the quarter.
Clear Street sold 10 LakeShore Biopharma shares in Q2 2023, an estimated $160.
Clear Street first reported a position in LakeShore Biopharma in Q1 2023 and held it in 1 quarter.
Clear Street's LakeShore Biopharma position peaked at $160 in Q1 2023.
16 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q2 2023.

Based on Clear Street's 13F filing for Q2 2023, filed 14 Aug 2023.